Astrazeneca
AZN on NYSE. Market value $243.3bn.
Should I look at this?
We have not checked this company yet
This is not advice.
Who owns it
12 long-term investors we follow own it, up from 10 last quarter. 1,498 funds in all.
- Sanders CapitalLew Sanders
- Value
- $1.3bn
- Share of fund
- 1.3%
- Platinum Investment ManagementPlatinum team
- Value
- $9m
- Share of fund
- 2.2%
- First Manhattan Co.First Manhattan partners
- Value
- $664,978
- Share of fund
- <0.1%
- Gotham Asset ManagementJoel Greenblatt
- Value
- $380,567
- Share of fund
- <0.1%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Causeway Capital ManagementSarah Ketterer | $1.8bn | 19.0% | Added |
| Sanders CapitalLew Sanders | $1.3bn | 1.3% | |
| Boston PartnersBoston Partners team | $597m | 0.5% | Added |
| Glenview Capital ManagementLarry Robbins | $35m | 0.7% | New |
| Cambiar InvestorsBrian Barish | $25m | 1.1% | Cut |
| Dodge & CoxDodge & Cox investment committee | $11m | <0.1% | Cut |
| Platinum Investment ManagementPlatinum team | $9m | 2.2% | |
| Troy Asset ManagementSebastian Lyon (founder) | $7m | 0.2% | New |
| Polen CapitalDan Davidowitz | $4m | <0.1% | Cut |
| Horizon KineticsMurray Stahl | $950,944 | <0.1% | Cut |
| First Manhattan Co.First Manhattan partners | $664,978 | <0.1% | |
| Gotham Asset ManagementJoel Greenblatt | $380,567 | <0.1% |
Largest holders overall
- Evelyn Partners Group$41.5bn
- Banque Cantonale Vaudoise$11.3bnNew
- Investor AB$9.8bn
- Vanguard Capital Management$8.5bn
- Capital International Investors$6.5bn
- Norges Bank$6.3bnNew
- Capital World Investors$5.6bnAdded
- FMR$5.4bnCut
- Wellington Management Group LLP$5.4bnAdded
- Legal & General Group$4.8bn
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
2 investors own more than 5%.
- BlackRock, Inc.Passive investor7.6%Since 31 March 2025
- Vanguard Capital ManagementPassive investor5.0%Since 31 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
BlackRock, Inc. Passive investor | 7.6% | 31 March 2025 | |
Vanguard Capital Management Passive investor | 5.0% | 31 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 1 insider bought $3,249 of shares on the open market. 1 sold $2m.
- Sharma ManiSee RemarksBought
- Date
- 8 August 2026
- Shares
- 20
- Price
- $160.57
- Value
- $3,249
- Sharma ManiSee RemarksSold
- Date
- 20 May 2026
- Shares
- 11,893
- Price
- $185.78
- Value
- $2m
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 8 August 2026 | Sharma Mani See Remarks | Bought | 20 | $160.57 | $3,249 |
| 20 May 2026 | Sharma Mani See Remarks | Sold | 11,893 | $185.78 | $2m |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
Astrazeneca doesn’t file a US annual report (10-K), so we haven’t checked it.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.